insertions), wherein (i) residue 32 is any amino acid, optionally not serine, (ii) residue 126 is not leucine, and (iii) residue 243 is not glutamate.

13. The fusion polypeptide of claim 12, wherein either (A) the first amino acid sequence is SEQ ID NO: 47 (*e.g.* SEQ ID NO: 50) and the second amino acid sequence is SEQ ID NO: 48 (*e.g.* SEQ ID NO: 51) or (B) the first amino acid sequence is SEQ ID NO: 31 (*e.g.* SEQ ID NO: 45) and the second amino acid sequence is SEQ ID NO: 32 (*e.g.* SEQ ID NO: 44).

14. The fusion polypeptide of any one of claims 11 to 13, also including a v1 fHbp sequence, wherein the polypeptide can, when administered to a human, elicit an antibody response that is bactericidal against a meningococcus which expresses a v1 fHbp, a meningococcus which expresses a v2 fHbp, and a meningococcus which expresses a v3 fHbp; and wherein, optionally, the v1 fHbp sequence includes a mutation which gives it a lower affinity for human fH than a meningococcal polypeptide consisting of SEQ ID NO: 46 *e.g.* wherein the v1 fHbp sequence has amino acid sequence SEQ ID NO: 49 or 52.

15. The fusion polypeptide of claim 14, comprising the amino acid sequence of SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, or SEQ ID NO: 30.

16. An immunogenic composition comprising a pharmaceutically acceptable carrier and a polypeptide selected from the polypeptides according to claims 1-10 and the fusion polypeptides according to claims 11-15.

17. An immunogenic composition according to claim 16, further comprising an adjuvant.

18. Use of an immunogenic composition according to claim 16 in the manufacture of a medicament for raising an antibody response in a human.